On Tuesday, Shares of Allegheny Technologies Incorporated (NYSE:ATI), lost -13.56% to $21.67.
Allegheny Technologies Incorporated, stated second quarter 2015 sales of $1.02 billion and a net loss attributable to ATI of $16.4 million, or $(0.15) per share. Results were adversely affected by lower demand in both the Flat Rolled Products and High Performance Materials and Components segments. Sales declined 9% contrast to the first quarter 2015, when ATI stated net income of $10.0 million, or $0.09 per share. Results for the second quarter 2014 were sales of $1.12 billion and a net loss from ongoing operations attributable to ATI of $3.8 million, or $(0.03) per share.
“This was a challenging quarter due to business conditions in the Flat Rolled Products segment and further weakening in demand from the oil & gas market in the High Performance Materials and Components segment,” said Rich Harshman, Chairman, President and CEO.
Allegheny Technologies Incorporated produces and sells specialty materials and components worldwide. The company operates through two segments, High Performance Materials and Components; and Flat-Rolled Products.
Shares of Synthetic Biologics Inc (NYSEMKT:SYN), inclined 7.57% to $3.41, during its last trading session.
Synthetic Biologics, declared that it has closed the public offering of 15.3 million shares of common stock, counting the fully exercised over-allotment option by the underwriters covering 2.0 million shares, at an offering price of $3.00 per share. The total gross proceeds of the offering, counting the exercise in full of the over-allotment option, were about $46.0 million. Net proceeds to the Company, after deducting the underwriters’ discount and other estimated expenses, are predictable to be about $42.6 million.
The Company anticipates using the net proceeds from the offering to fund its clinical programs counting Phase 2 clinical candidates, SYN-004 for the prevention of C. difficile and SYN-010 for the treatment of irritable bowel syndrome with constipation (IBS-C), research & development, potential licensing and acquisition of intellectual property, investments in and acquisition of complementary businesses or partnerships, and for general corporate purposes.
Synthetics Biologics, Inc., a clinical-stage biotechnology company, develops pathogen-specific therapies for serious infections and diseases with a focus on protecting the microbiome.
Finally, Markwest Energy Partners LP (NYSE:MWE), ended its last trade with - 1.50% loss, and closed at $64.86.
MarkWest Energy Partners, L.P., declared that the Board of Directors of the General Partner of MarkWest Energy Partners, L.P., declared a cash distribution of $0.92 per common unit for the second quarter of 2015, for an implied annual rate of $3.68 per common unit. The second quarter 2015 distribution represents an enhance of $0.04 per common unit, or 4.5 percent, contrast to the second quarter 2014 distribution and an enhance of $0.01 per common unit, or 1.1 percent, contrast to the first quarter 2015 distribution.
The second quarter 2015 distribution is payable August 14, 2015, to unitholders of record on August 6, 2015. The ex-dividend date is August 4, 2015.
MarkWest Energy Partners, L.P. engages in the gathering, processing, and transportation of natural gas. The company is also involved in the gathering, transportation, fractionation, storage, and marketing of natural gas liquids; and the gathering and transportation of crude oil.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
